

**AGITG Publications**

Year	No.	Manuscripts	Trial
2019	1	Oar A, Lee M, Le H, Hruby G, Dalfsen R, Pryor D, Lee D, Chu J, Holloway L, Briggs A, Barbour A, Chander S, Ng SP, Samra J, Shakeshaft J, Goldstein D, Nguyen N, Goodman KA, Chang DT, Kneebone A, Australasian Gastrointestinal Trials Group (AGITG) and Trans-Tasman Radiation Oncology Group (TROG) Guidelines for Pancreatic Stereotactic Body Radiation Therapy (SBRT). <i>Practical Radiation Oncology</i> 2019.	MASTERPLAN
2019	2	Chua YJ, Pavlakis N, Sjoquist K, Martin AJ, Tsoibanis E, Yip S, Bang Y-J, Alcindor T, O'callaghan CJ, Bekaii-Saab TS, Grothey A, Chen L-T, Simes J, Zalcberg JR, Goldstein D, Komatsu Y, Machida N, Esaki T, Hara H, Shitara K, Randomised Phase 3 Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) - INTEGRATE II. <i>Ann Oncology</i> 2019; 30; October.	INTEGRATE II
2019	3	Rico GT, Price T, Tebbutt N, Hardingham J, Lee C, Buizen L, Wilson K, GebSKI V, Townsend A, Right or left primary site of colorectal cancer: outcomes from the molecular analysis of the AGITG MAX trial, <i>Clinical Colorectal Cancer</i> (2019), doi: <a href="https://doi.org/10.1016/j.clcc.2018.12.002">https://doi.org/10.1016/j.clcc.2018.12.002</a>	MAX
2019	4	Stevenson A, Solomon M, Brown C, Lumley J, Hewett P, Clouston A, GebSKI V, Wilson K, Hague W, Simes J. Disease-free Survival and Local Recurrence After Laparoscopic-assisted Resection or Open Resection for Rectal Cancer: The Australasian Laparoscopic Cancer of the Rectum Randomised Clinical Trial. <i>Ann Surg</i> 2019;269:596-602	A La CaRT
2018	5	Segelov E, Sieber O, Chia JWK, Williams DS. COX2 and HLA immunohistochemical (IHC) staining in colorectal tumour samples from patients participating in the ASCOLT clinical trial of adjuvant aspirin therapy. <i>J Clin Oncol.</i> 2018 Feb; 36 (4 suppl), 695	ASCOLT
2018	6	Mooi JK, Wirapati P, Asher R, Lee CK, Savas PS, Price TJ, Townsend A, Hardingham J, Buchanan D, Williams D, Tejpar S, Mariadason JM, Tebbutt NC. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: Molecular analysis of the AGITG MAX clinical trial. <i>Ann Oncol.</i> 2018; Nov 1; 29(11):2240-2246. doi.org/10.1093/annonc/mdy410	MAX
2018	7	Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, Souglakos J, Shi Q, Kerr R, Labianca R, Meyerhardt JA, Vernerey D, Yamanaka T, Boukvinas I, Meyers JP, Renfro LA, Niedzwiecki D, Watanabe T, Torri V, Saunders M, Sargent DJ, Andre T, Iveson T. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer <i>N Engl J Med.</i> 2018 Mar 29;378(13):1177-1188.	IDEA (includes SCOT)
2018	8	Jonker DJ, Nott L, Yoshino T, Gill S, Shapiro J, Ohtsu A, Zalcberg J, Vickers MM, Wei AC, Gao Y, Tebbutt NC, Markman B, Price T, Esaki T, Koski S, Hitron M, Li W, Li Y, Magoski NM, Li CJ, Simes J, Tu D, O'Callaghan CJ. Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. <i>Lancet Gastroenterol Hepatol</i> , 2018 Apr; 3(4):263-270. doi: 10.1016/S2468-1253(18)30009-8. Epub 2018 Feb 1	CO.23
2018	9	Shapiro JD, Thavaneswaran S, Underhill CR, Robledo KP, Karapetis CS, Day FL, Nott LM, Jefford M, Chantrill LA, Pavlakis N, Tebbutt NC, Price TJ, Khasraw M, Van Hazel GA, Waring PM, Tejpar S, Simes J, GebSKI VJ, Desai J, Segelov E, Cetuximab alone or with irinotecan for resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type metastatic colorectal cancer: the AGITG randomised phase II ICECREAM study, <i>Clin Colorectal Cancer</i> 2018 Dec; 17(4):313-319. doi: 10.1016/j.clcc.2018.06.002. Epub 2018 Jun 8.	ICECREAM
2018	10	Tang M, Price TJ, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, Burge M. Adjuvant therapy for resected colon cancer 2017, including the idea analysis. <i>Expert Review of Anticancer Therapy.</i> 2018;18(4):339-349.	Review
2018	11	André T, Vernerey D, Mineur L, Bennouna J, Desrame J, Faroux R, Fratte S, Hug de Larauze M, Paget-Bailly S, Chibaudel B, Bez J, Dauba J, Louvet C, Lepere C, Dupuis O, Becouarn Y, Mabro M, Egretreau J, Bouche O, Deplanque G, Ychou M, Galais MP, Ghiringhelli F, Dourthe LM, Bachet JB, Khalil A, Bonnetain F, de Gramont A, Taieb J; for PRODIGE investigators, GERCOR, Fédération Française de Cancérologie Digestive, and UNICANCER. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. <i>J Clin Oncol.</i> 2018 May 20;36(15):1469-1477. doi: 10.1200/JCO.2017.76.0355. Epub 2018 Apr 5.	IDEA (includes SCOT)
2018	12	Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Scudder C, Boyd KA, Briggs A, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer: an international, randomised, phase 3, non-inferiority trial. <i>Lancet Oncol.</i> 2018 Apr;19(4):562-578.doi: 10.1016/S1470-2045(18)30093-7.	SCOT
2018	13	Leong T, Editorial - A CRITICAL period for chemoradiotherapy in gastric cancer. <i>Lancet Oncol.</i> 2018 May;19	TOPGEAR
2017	14	Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, Judson IR, Schoffski P, Leyvraz S, Italiano A, Grunwald V, Pousa AL, Kotasek J, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn P, Litiere S, Marreaud S, van der Graaf W, Gronchi A, Verweij J. Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long- term analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group intergroup phase III randomized trial on imatinib at two dose levels. <i>Journal of Clinical Oncology</i> 2017; 35(15): 1713-1720.	EORTC 62005
2017	15	Leong T, Smithers BM, Haustermans K, Michael M, GebSKI V, Miller D, Zalcberg J, Boussioutas A, Findlay M, O'Connell RL, Verghis J, Willis D, Kron T, Crain M, Murray WK, Lordick F, Swallow C, Darling G, Simes J, Wong R. TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG. <i>Annals of Surgical Oncology</i> 2017; 24(8): 2252-2258.	TOPGEAR
2017	16	Martin AJ, Gibbs E, Sjoquist K, Pavlakis N, Simes J, Price T, Shannon J, Gill S, Jain V, Liu G, Kannourakis G, Kim YH, Kim JW, Goldstein D. Health-related quality of life associated with regorafenib treatment in refractory advanced gastric adenocarcinoma. <i>Gastric Cancer.</i> Online 18 Aug 2017.	INTEGRATE
2017	17	McNamara MG, Bridgewater J, Lopes A, Wasan H, Malka D, Jensen LH, Okusaka T, Knox JJ, Wagner D, Cunningham D, Shannon J, Goldstein D, Moehler M, Bekaii-Saab T, Valle JW. 1Systemic therapy in younger and elderly patients with advanced biliary cancer: subanalysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> (2017) 17:262	TACTIC
2017	18	Segelov E, Lordick F, Goldstein D, Chantrill LA, Croagh D, Lawrence B, Arnold D, Chau I, Obermannova R, Price TJ. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. <i>Expert Review of Anticancer Therapy</i> 2017; 17(10): 951-964.	Review
2017	19	Thavaneswaran S, Kok PS, Price T. Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> 2017; 17(10) 965-979.	Review
2016	20	Chandrasegaram MD, Chen JW, Price TJ, Zalcberg J, Sjoquist K, Merrett ND. Advances in molecular pathology and treatment of periampullary cancers. <i>Pancreas</i> 2016; 45(1): 32-39.	Review

Year	No.	Manuscripts	Trial
2016	21	Bridgewater J, Lopes H, Wasan H, Malka D, Jensen L, Okusaka T, Knox J, Wagner D, Cunningham D, Shannon J, Goldstein D, Moehler M, Bekaii-Saab T, McNamara MG, Valle JW. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. <i>Annals of Oncology</i> 2016; 27: 134–140.	TACTIC
2016	22	Ferraro D, Goldstein D, O'Connell RL, Zalberg JR, Sjoquist KM, Tebbutt NC, Grimison P, McLachlan S, Lipton LL, Vasey P, GebSKI VJ, Aiken C, Cronk M, Ng S, Karapetis CS, Shannon J. TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer. <i>Cancer Chemotherapy and Pharmacology</i> 2016; 78(2): 361–367.	TACTIC
2016	23	Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz- Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De Gramont A, Sargent DJ, Grothey A. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. <i>Lancet Oncology</i> 2016; 17(12): 1709–1719.	ARCAD
2016	24	Gandy RC, Barbour AP, Samra J, Nikfarjam M, Haghighi K, Kench JG, Saxena P, Goldstein D. Refining the care of patients with pancreatic cancer: the AGITG Pancreatic Cancer Workshop consensus. <i>Medical Journal of Australia</i> 2016; 204(11): 419–422.	Review
2016	25	Gormly KL, Coscia C, Wells T, Tebbutt N, Harvey JA, Wilson K, Schmoll HJ, Price T. MRI rectal cancer in Australia and New Zealand: an audit from the PETACC-6 trial. <i>Journal of Medical Imaging and Radiation Oncology</i> 2016; 60(5): 607–615.	PETACC-6
2016	26	Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouche O, Shannon J, Andre T, Mineur L, Chibaudel B, Bonnetain F, Louvet C. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. <i>JAMA</i> 2016; 315(17): 1844–1853.	LAP07
2016	27	Kerr RS, Love S, Segelov E, Johnstone E, Falcon B, Hewett P, Weaver A, Church D, Scudder C, Pearson S, Julier P, Pezzella F, Tomlinson I, Domingo E, Kerr DJ. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> 2016; 17(11): 1543–1557.	QUASAR 2
2016	28	Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd LE, Jonker DJ, O'Callaghan CJ, Zalberg JR, Karapetis CS, Dobrovic A. Fc-gamma receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer. <i>Clinical Cancer Research</i> 2016; 22(10): 2435–2444.	CO.17
2016	29	McLachlan SA, Fisher RJ, Zalberg J, Solomon M, Burmeister B, Goldstein D, Leong T, Ackland SP, McKendrick J, McClure B, Mackay J, Ngan SY. The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short- course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). <i>European Journal of Cancer</i> 2016; 55: 15–26.	TROG 01.04
2016	30	Pavlikis N, Sjoquist KM, Martin AJ, Tsobanis E, Yip S, Kang YK, Bang YJ, Alcindor T, O'Callaghan CJ, Burnell MJ, Tebbutt NC, Rha SY, Lee J, Cho JY, Lipton LR, Wong M, Strickland A, Kim JW, Zalberg JR, Simes J, Goldstein D. Regorafenib for the treatment of advanced gastric cancer (INTEGRATE): a multinational placebo- controlled phase II trial. <i>Journal of Clinical Oncology</i> 2016; 34(23): 2728–2735.	INTEGRATE
2016	31	Price TJ, Thavaneswaran S, Burge M, Segelov E, Haller DG, Punt CJ, Arnold D, Karapetis CS, Tebbutt NC, Pavlikis N, Gibbs P, Shapiro JD. Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. <i>Expert Review of Anticancer Therapy</i> 2016; 16(5): 557–571.	Review
2016	32	Schofield PE, Stockler MR, Zannino D, Tebbutt NC, Price TJ, Simes RJ, Wong N, Pavlikis N, Ransom D, Moylan E, Underhill C, Wyld D, Burns I, Ward R, Wilcken N, Jefford M. Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer. <i>Supportive Care in Cancer</i> 2016; 24(1): 401–408.	MAX
2016	33	Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, GebSKI VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavlikis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro JD. Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study. <i>Journal of Clinical Oncology</i> 2016; 34(19): 2258–2264.	ICECREAM
2016	34	Segelov E, Waring P, Desai J, Wilson K, GebSKI V, Thavaneswaran S, Elez E, Underhill C, Pavlikis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Price T, Tejjar S, Tebbutt N, Shapiro J. ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. <i>BMC Cancer</i> 2016; 16: 339.	ICECREAM
2016	35	Tebbutt NC, Price TJ, Ferraro DA, Wong N, Veillard AS, Hall M, Sjoquist KM, Pavlikis N, Strickland A, Varma SC, Cooray P, Young R, Underhill C, Shannon JA, Ganju V, GebSKI V. Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. <i>British Journal of Cancer</i> 2016; 114(5): 505–509.	ATTAX3
2016	36	Thavaneswaran S, Price TJ. Optimal therapy for resectable rectal cancer. <i>Expert Review of Anticancer Therapy</i> 2016; 16(3): 285–302.	Review
2016	37	Vickers MM, Lee C, Tu D, Wheatley-Price P, Parulekar W, Brundage MD, Moore MJ, Au H, O'Callaghan CJ, Jonker DJ, Ringash J, Goldstein D. Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. <i>Pancreatology</i> 2016; 16(6): 1106–1112.	PA.3
2015	38	Brule SY, Jonker DJ, Karapetis CS, O'Callaghan CJ, Moore MJ, Wong R, Tebbutt NC, Underhill C, Yip D, Zalberg JR, Tu D, Goodwin RA. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. <i>European Journal of Cancer</i> 2015; 51(11): 1405–1414.	CO.17
2015	39	Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WTA, Zalberg JR, Litière S, Blay J-Y. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. <i>Journal of Clinical Oncology</i> 2015; 33(36): 4276–4283.	EORTC 62024
2015	40	Chan DL, Pavlikis N, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Segelov E. Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature [correction 10(9):e0138916. <i>PLoS ONE</i> 2015; 10(8): e0135599.	Review
2015	41	Chan MM, Sjoquist KM, Zalberg JR. Clinical utility of ramucirumab in advanced gastric cancer. <i>Biologics</i> 2015; 9: 93–105.	Review

Year	No.	Manuscripts	Trial
2015	42	Chandrasegaram MD, Goldstein D, Simes J, GebSKI V, Kench JG, Gill AJ, Samra JS, Merrett ND, Richardson AJ, Barbour AP. Meta-analysis of radical resection rates and margin assessment in pancreatic cancer. <i>British Journal of Surgery</i> 2015; 102(12): 1459–1472.	Review
2015	43	Chantrill LA, Nagrial AM, Watson C, Johns AL, Martyn-Smith M, Simpson S, Mead S, Jones MD, Samra JS, Gill AJ, Watson N, Chin VT, Humphris JL, Chou A, Brown B, Morey A, Pajic M, Grimmond SM, Chang DK, Thomas D, Sebastian L, Sjoquist K, Yip S, Pavlakis N, Asghari R, Harvey S, Grimison P, Simes J, Biankin AV. Precision medicine for advanced pancreas cancer: the Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial. <i>Clinical Cancer Research</i> 2015; 21(9): 2029-2037.	IMPACT
2015	44	Lee CK, Goldstein D, Gibbs E, Joensuu H, Zalcbberg J, Verweij J, Casali PG, Maki RG, Cioffi A, McArthur G, Lord SJ, Yip D, Kanjanapan Y, Rutkowski P. Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. <i>European Journal of Cancer</i> 2015; 51(7): 852- 860.	EORTC 62005
2015	45	Leong T, Smithers BM, Michael M, GebSKI V, Boussoutias A, Miller D, Simes J, Zalcbberg J, Hausterman K, Lordick F, Schuhmacher C, Swallow C, Darling G, Wong R. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). <i>BMC Cancer</i> 2015; 15: 532.	TOPGEAR
2015	46	Nagrial AM, Chin VT, Sjoquist KM, Pajic M, Horvath LG, Biankin AV, Yip D. Second-line treatment in inoperable pancreatic adenocarcinoma: a systematic review and synthesis of all clinical trials. <i>Critical Reviews in Oncology/Hematology</i> 2015; 96(3): 483–497.	Review
2015	47	Price TJ, Bruhn MA, Lee CK, Hardingham JE, Townsend AR, Mann K, J. S, Weickhardt A, Wrin JW, Wilson K, GebSKI V, Van Hazel G, Robinson B, Cunningham D, Tebbutt NC. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the Phase III AGITG MAX involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. <i>British Journal of Cancer</i> 2015; 112: 963-970.	MAX
2015	48	Roohullah A, Wong HLS, K.M., Gibbs P, Field K, Tran B, Shapiro J, McKendrick J, Yip D, Nott L, GebSKI V, Ng W, Chua W, Price T, Tebbutt N, Chantrill L. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. <i>World Journal of Gastroenterology</i> 2015; 21(17): 5352- 5358.	MAX
2015	49	Sjoquist KM, Zalcbberg JR. Gastric cancer: past progress and present challenges [editorial]. <i>Gastric Cancer</i> 2015; 18(2): 205-209.	Review
2015	50	Stevenson AR, Solomon MJ, Lumley JW, Hewett P, Clouston AD, GebSKI VJ, Davies L, Wilson K, Hague W, Simes J. Effect of laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer: the ALaCaRT randomized clinical trial. <i>JAMA</i> 2015; 314(13): 1356–1363.	A La CaRT
2015	51	Tanis E, Julie C, Emile JF, Mauer M, Nordlinger B, Aust D, Roth A, Lutz MP, Gruenberger T, Wrba F, Sorbye H, Bechstein W, Schlag P, Fisseler A, Ruers T. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. <i>European Journal of Cancer</i> 2015; 51(17): 2708–2717.	EORTC 40983
2015	52	Weickhardt AJ, Williams DS, Lee CK, Chionh F, Simes J, Murone C, Wilson K, Parry MM, Asadi K, Scott AM, Punt CJ, Nagtegaal ID, Price TJ, Mariadason JM, Tebbutt NC. Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. <i>British Journal of Cancer</i> 2015; 113(1): 37–45.	MAX
2014	53	Bruhn MA, Townsend AR, Lee CK, Shivasami A, Price TJ, Wrin J, Arentz G, Tebbutt NC, Hocking C, Cunningham D, Hardingham JE, on behalf of the BHI in collaboration with AGITG. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. <i>International Journal of Cancer</i> 2014; 135(3): 731–741.	MAX
2014	54	Carter HE, Zannino D, Simes RJ, Schofield DJ, Howard K, Zalcbberg JR, Price TJ, Tebbutt NC. The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study. <i>European Journal of Cancer</i> 2014; 50(3): 535–543.	MAX
2014	55	Ferraro D, Zalcbberg J. Regorafenib in gastrointestinal stromal tumors: clinical evidence and place in therapy. <i>Therapeutic Advances in Medical Oncology</i> 2014; 6(5): 222–228.	Review
2014	56	Greenhalf W, Ghaneh P, Neoptolemos JP, Palmer DH, Cox TF, Lamb RF, Garner E, Campbell F, Mackey JR, Costello E, Moore MJ, Valle JW, McDonald AC, Carter R, Tebbutt NC, Goldstein D, Shannon J, Derveniz C, Glimelius B, Deakin M, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthony A, Halloran CM, Mayerle J, Oláh A, Jackson R, Rawcliffe CL, Scarpe A, Bassi C, Büchler MW, and for the European Study Group for Pancreatic Cancer. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. <i>Journal of the National Cancer Institute</i> 2014; 106(1): djt347.	ESPAC-3
2014	57	Hocking C, Hardingham J, Broadbridge V, Townsend AR, Tebbutt N, Cooper J, Ruszkiewicz A, Lee C, Price TJ. Can we accurately report PTEN status in advanced colorectal cancer? <i>BMC Cancer</i> 2014; 14: 128.	MAX
2014	58	Hohenberger P, Bonvalot S, Litiere S, Rutkowski P, van Coevorden F, Meeus P, Marréaud S, Raventos VA, Kotasek D, Padbury R, Van der Graaf W, Gronchi A. Surgical resection of metastatic GIST on imatinib delays recurrence and death: results of a cross-match comparison in the EORTC intergroup study 62005, aimed at assessing the clinical activity of imatinib at two dose levels in patients with unresectable or metastatic GIST. <i>Connective Tissue Oncology Society</i> ; 15–18 Oct 2014; Berlin.	EORTC 62005
2014	59	Jonker D, Karapetis C, Harbison C, O'Callaghan C, Tu D, Simes R, Malone D, Langer C, Tebbutt N, Price T, Shapiro J, Siu L, Wong R, Bjarnason G, Moore M, Zalcbberg J, Khambata-Ford S. Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. <i>British Journal of Cancer</i> 2014; 110(3): 648–55.	CO.17
2014	60	Karapetis CS, Jonker D, Daneshmand M, Hanson JE, O'Callaghan CJ, Marginean C, Zalcbberg JR, Simes J, Moore MJ, Tebbutt NC, Price TJ, Shapiro JD, Pavlakis N, Gibbs P, Van Hazel GA, Lee U, Haq R, Virk S, Tu D, Lorimer IA. PIK3CA, BRAF and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer—results from NCIC CTG/AGITG CO.17. <i>Clinical Cancer Research</i> 2014; 20(3): 744–753.	CO.17
2014	61	Price TJ, Segelov E, Burge M, Haller DG, Tebbutt NC, Karapetis CS, Punt CJ, Pavlakis N, Arnold D, Gibbs P, Shapiro JD. Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. <i>Expert Review of Anticancer Therapy</i> 2014; 14(12): 1477–1493.	Review
2014	62	Ransom D, Wilson K, Fournier M, Simes RJ, GebSKI V, Yip D, Tebbutt N, Karapetis CS, Ferry D, Gordon S, Price TJ. Final results of Australasian Gastro-Intestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. <i>Annals of Oncology</i> 2014; 25(1): 117–121. 13.	ARCTIC
2014	63	Ringash J, Au HJ, Siu LL, Shapiro JD, Jonker DJ, Zalcbberg JR, Moore MJ, Strickland A, Kotb R, Jeffery M, Alcindor T, Ng S, Salim M, Sabesan S, Easaw JC, Shannon J, El-Tahche F, Walters I, Tu D, O'Callaghan CJ, NCIC Clinical Trials Group, Australasian Gastrointestinal Trials Group. Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial. <i>Cancer</i> 2014; 120(2): 181–189.	CO.20



Year	No.	Manuscripts	Trial
2014	64	Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, Wang H, Love S, Julier P, Scudder C, Nicholson G, Gonzalez-Neira A, Martin M, Sargent DJ, Green E, McLeod H, Zanger UM, Schwag M, Seymour MT, Thompson L, Lacas B, Boige V, Ribelles N, Afzal S, Enghusen H, Etienne-Grimaldi MC, Milano G, Wadelius M, Glimelius B, Garmo H, Gusella M, Lecomte T, Laurent-Puig, Martinez-Balibrea E, Sharma R, Garcia-Foncillas J, Kleibl Z, Morel A, Pignon JP, Midgley RS, Kerr D, Tomlinson I. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. <i>Journal of Clinical Oncology</i> 2014; 32(10): 1031–1039.	QUASAR 2
2014	65	Sommeijer DW, Karapetis CS, Zalcborg JR, Tu D, Jonker DJ, Simes J, Tebbutt N, Yip D, Price TJ, O'Callaghan CJ. The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17. <i>Acta Oncologica</i> 2014; 53(7): 877–884.	CO.17
2014	66	Valle JW, Palmer D, Jackson R, Cox T, Neoptolemos JP, Ghaneh P, Rawcliffe CL, Bassi C, Stocken DD, Cunningham D, O'Reilly D, Goldstein D, Robinson BA, Karapetis C, Scarfe A, Lacaine F, Sand J, Izbicki JR, Mayerle J, Dervenis C, Oláh A, Butturini G, Lind PA, Middleton MR, Anthony A, Sumpter K, Carter R, Büchler MW. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. <i>Journal of Clinical Oncology</i> 2014; 32(6): 504–512.	ESPAC-3
2013	67	Harbison CT, Horak CE, Ledezine JM, Mukhopadhyay P, Malone DP, O'Callaghan C, Jonker DJ, Karapetis CS, Khambata-Ford S, Gustafson N, Trifan OC, Chang SC, Ravetto P, Green GA 4th. Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial. <i>Archives of Pathology &amp; Laboratory Medicine</i> 2013; 137(6): 820–827.2	CO.17
2013	68	Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guane ZZ, Michell L, Waterkamp D, Tabernerog J. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. <i>Oncologist</i> 2013; 18(9): 1004–1012.	MAX
2013	69	Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Mauer M, Tanis E, Van Cutsem E, Scheithauer W, Gruenberger T, for the EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro- Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> 2013; 14(12): 1208–1215.	EORTC 40983
2013	70	Price T, Hardingham J, Lee C, Townsend A, Wrin J, Wilson K, Weickhardt A, Simes R, Murone C, Tebbutt N. Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer receiving bevacizumab. <i>Cancer Medicine</i> 2013; 2(3): 277–285.	MAX
2013	71	Siu L, Shapiro J, Jonker D, Karapetis C, Zalcborg J, Simes J, Couture F, Moore M, Price T, Siddiqui J, Nott L, Charpentier D, Liauw W, Sawyer M, Jefford M, Magoski N, Haydon A, Walters I, Ringash J, Tu D, O'Callaghan C. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 trial. <i>Journal of Clinical Oncology</i> ; 31(19): 2477-2484.	CO.20
2013	72	Sjoquist KM, Zalcborg JR. Clinical trials: advancing national cancer care. <i>Cancer Forum</i> 2013; 37(1): 80–87.	Review
2013	73	Tebbutt NC, Parry MM, Zannino D, Strickland AH, Van Hazel GA, Pavlakis N, Ganju V, Mellor D, Dobrovic A, Gebbski VJ, on behalf of the Australasian Gastro-Intestinal Trials Group (AGITG). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. <i>British Journal of Cancer</i> 2013; 108(4): 771–774.	ATTAX2
2013	74	Vickers MM, Karapetis CS, Tu D, O'Callaghan CJ, Price TJ, Tebbutt NC, Van Hazel G, Shapiro JD, Pavlakis N, Gibbs P, Blondal J, Lee U, Meharchand JM, Burkes RL, Rubin SH, Simes J, Zalcborg JR, Moore MJ, Zhu L, Jonker DJ. Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. <i>Annals of Oncology</i> 2013; 24(4): 953–960.	CO.17
2012	75	Clarke SJ, Yip S, Brown C, van Hazel GA, Ransom DT, Goldstein D, Jeffrey GM, Tebbutt NC, Buck M, Lowenthal RM, Boland A, Gebbski V, Zalcborg J, Simes RJ. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer: results of a randomised phase II study (DaVINCI) and meta-analysis [corrected]. <i>European Journal of Cancer</i> 2011; 47(12): 1826–1836. 1.	Da Vinci
2012	76	Dear RF, Barratt AL, Evans A, Simes J, Newsom J, Kent D, Crossing S, Holliday C, Segelov E, Hruby G, Tattersall MH. Identifying and prioritising gaps in colorectal cancer trials research in Australia. <i>Medical Journal of Australia</i> 2012; 197(9): 507–511.	Review
2012	77	Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter, IWT, Hruby G, Horvath L, Bydder S, Undercill C, Harvey J, Gebbski VJ; on behalf of the Australasian Gastro-Intestinal Trials Group. The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine–oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer. <i>British Journal of Cancer</i> 2012; 106(1): 61–69.	Gofurtgo
2012	78	Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthony A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW, European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. <i>JAMA</i> 2012; 308(2): 147–156.	ESPAC-3
2012	79	Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, Wiltshire K, Ngan S, Kachnic L. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity- modulated radiotherapy in anal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> 2012; 83(5): 1455–1462.	Review
2012	80	Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, Ackland SP, Schache D, McClure B, McLachlan SA, McKendrick J, Leong T, Hartoepanu C, Zalcborg J, Mackay J. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. <i>Journal of Clinical Oncology</i> 2012; 30(31): 3827–3833.	TROG 01.04
2012	81	Price TJ, Zannino D, Wilson K, Simes J, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. <i>Annals of Oncology</i> 2012; 23(6): 1353–1536.	MAX

Year	No.	Manuscripts	Trial
2012	82	Sorbye H, Mauer M, Gruenberger T, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Van Cutsem E, Scheithauer W, Lutz MP, Nordlinger B; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK (CRUK); Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro- Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). <i>Annals of Surgery</i> 2012; 255(3): 534–539.	EORTC 40983
2012	83	Vickers MM, Powell ED, Asmis TR, Jonker DJ, Hilton JF, O'Callaghan CJ, Tu D, Parulekar W, Moore MJ. Comorbidity, age and overall survival in patients with advanced pancreatic cancer—results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo. <i>European Journal of Cancer</i> 2012; 48(10): 1434–1442.	PA.3
2011	84	Asmis TR, Powell E, Karapetis CS, Jonker DJ, Tu D, Jeffery M, Pavlakis N, Gibbs P, Zhu L, Dueck DA, Whittom R, Langer C, O'Callaghan CJ. Comorbidity, age and overall survival in cetuximab- treated patients with advanced colorectal cancer (ACRC)—results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. <i>Annals of Oncology</i> 2011; 22(1): 118–126.	CO.17
2011	85	Goldstein D, Gainford MC, Brown C, Tebbutt N, Ackland SP, van Hazel G, Jefford M, Abdi E, Selva-Nayagam S, GebSKI V, Miller D, Shannon J. Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. <i>Cancer Chemotherapy and Pharmacology</i> 2011; 67(3): 519–525.	ABC
2011	86	Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, Chua A, Shivasami A, Cummins MM, Murone C, Tebbutt NC. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. <i>Journal of Clinical Oncology</i> 2011; 29(19): 2675–2682.	MAX
2011	87	Sjoquist K, Burmeister B, Smithers BM, Zalcberg JR, Simes J, Barbour A, GebSKI V; on behalf of the Australasian Gastro-Intestinal Trials Group (AGITG). Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. <i>Lancet Oncology</i> 2011; 12(7): 681–692.	IG9401
2011	88	Tebbutt NC, Murphy F, Zannino D, Wilson K, Cummins MM, Abdi E, Strickland AH, Lowenthal RM, Marx G, Karapetis C, Shannon J, Goldstein D, Nayagam SS, Blum R, Chantrill L, Simes RJ, Price TJ; on behalf of the Australasian Gastro-Intestinal Trials Group (AGITG). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. <i>Annals of Oncology</i> 2011; 22(8): 1834–1838.	MAX
2011	89	Yothers G, O'Connell M, Allegra C, Kuebler J, Colangelo L, Petrelli N, Wolmark N. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. <i>Journal of Clinical Oncology</i> 2011; 29(28): 3768–3774.	C-07
2010	90	De Roock S, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. Association of Kras p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. <i>JAMA</i> 2010; 304(16): 1812–1820.	CO.17
2010	91	MetaGIST: Gastrointestinal Stromal Tumor Meta-Analysis Group, Verweij J, Blay J, Debiec-Rychter M, Demetri G, Heinrich M, Borden E, Blanke C, Crowley J, Rankin C, Casali P, Von Mehren M, Fletcher C, Fletcher J, Owzar K, Zalcberg J, Simes J, Bramwell V. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. <i>Journal of Clinical Oncology</i> 2010; 28(7): 1247–1253.	EORTC 62005
2010	92	Neoptolemos JP, Stocken DD, Bassi C, Ghaneh P, Cunningham D, Goldstein D, Padbury R, Moore MJ, Gallinger S, Mariette C, Wente MN, Izbicki JR, Friess H, Lerch MM, Dervenis C, Oláh A, Butturini G, Doi R, Lind PA, Smith D, Valle JW, Palmer DH, Buckels JA, Thompson J, McKay CJ, Rawcliffe CL, Büchler, MW; for the European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. <i>JAMA</i> 2010; 304(10): 1073–1081.	ESPAC-3
2010	93	Tebbutt NC, Cummins MM, Sourjina T, Strickland AH, Van Hazel G, Ganju V, Gibbs D, Stockler M, GebSKI V, Zalcberg J; on behalf of the Australasian Gastro-Intestinal Trials Group. Randomised, non- comparative phase II study of weekly docetaxel with cisplatin and 5- fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. <i>British Journal of Cancer</i> 2010; 102: 475–481.	ATTAX
2010	94	Tebbutt NC, Wilson K, GebSKI VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua YJ, Zalcberg JR, Simes RJ, Price TJ. Capecitabine, bevacizumab and mitomycin C in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomised phase III MAX study. <i>Journal of Clinical Oncology</i> 2010; 28(19): 3191–3198.	MAX
2009	95	Au HJ, Karapetis CS, O'Callaghan CJ, Tu D, Moore MJ, Zalcberg J, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight GJ, Magoski NM, Brundage MD, Jonker DJ. Health-related quality of life in advanced colorectal cancer patients treated with cetuximab: overall and Kras-specific results of the NCIC CTG and AGITG CO.17 trial. <i>Journal of Clinical Oncology</i> 2009; 27(11): 1822–1828.	CO.17
2009	96	Chua W, Goldstein D, Lee C, Dhillon H, Michael M, Mitchell P, Clarke S, Iacopetta B. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> 2009; 101(6): 998–1004.	
2009	97	Hicks S, James R, Wong N, Tebbutt NC, Wilson S. A case study comparison of ethical review systems for multicentre clinical trials in Australia. <i>Medical Journal of Australia</i> 2009; 191(5): 280–282.	MAX CO.20
2009	98	Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, Issels R, Judson I, Schoffski P, Leyvraz S, Bui B, Hogendoorn PC, Sciort R, Blay JY. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the Intergroup EORTC-ISG-AGITG phase III trial. <i>Journal of Clinical Oncology</i> 2009;27(24): 3969–3974.	EORTC 62005
2009	99	Michael M, Price T, Ngan SY, Ganju V, Strickland AH, Muller A, Khamly K, Milner AD, Dilulio J, Matera A, Zalcberg JR, Leong T. A phase I trial of capecitabine + gemcitabine with radical radiation for locally advanced pancreatic cancer. <i>British Journal of Cancer</i> 2009; 100 (1): 37–43.	
2009	100	Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ; Working Group on Economic Analysis of the National Cancer Institute of Canada Clinical Trials Group—Australasian Gastrointestinal Interest Group. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. <i>Journal of the National Cancer Institute</i> 2009; 101(17): 1182–1192.	CO.17
2009	101	Neoptolemos JP, Stocken DD, Tudur Smith C, Bassi C, Ghaneh P, Owen E, Moore M, Padbury R, Doi R, Smith D, Büchler MW. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. <i>British Journal of Cancer</i> 2009; 100(2): 246–250.	ESPAC 1 ESPAC 3
2009	102	Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier P, Schneider U, Sciort R, Blay J, Hogendoorn P, on behalf of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. <i>Clinical Cancer Research</i> 2009; 15(12): 4191-4198.	EORTC 62005

Year	No.	Manuscripts	Trial
2008	103	Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. <i>New England Journal of Medicine</i> 2008; 359(17): 1757–1765.	CO.17
2008	104	Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro- Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. <i>Lancet</i> 2008; 371(9617): 1007–1016.	EORTC 40983
2008	105	Nowak AK, Cebon J, Hargreaves C, Dhillon H, Findlay M, GebSKI V, Stockler MR. Assessment of health-related quality of life and patient benefit as outcome measures for clinical trials in hepatocellular carcinoma. <i>Asia-Pacific Journal of Clinical Oncology</i> 2008; 4: 55-67.	AG0001H
2008	106	Sciot R, Debiec-Rychter M, Daugaard S, Fisher C, Collin F, Van Glabbeke M, Verweij J, Blay J-Y, Hogendoorn, PCW; on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group and the Australian Trials Group. Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumors. An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. <i>European Journal of Cancer</i> 2008; 44: 1855–1860.	EORTC 62005
2008	107	Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset J-F, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Goldberg R, Glynn-Jones R, Haller D, Kang Y-K, Kerr D, Labianca R, Minsky BD, Moore M, Nordlinger B, Rougier P, Scheithauer W, Schmoll H-J, Sobrero A, Tabernero J, Tempero M, Van de Velde C, Zalberg J. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. <i>Annals of Oncology</i> 2008; 19(suppl 6): vi1-vi8.	Review
2007	108	Findlay M, Storey D, GebSKI V, Hargreaves C, Cullingford G, Boyer M, Trotter J, Archer S, Davidson A, Johnston P, Yuen J, Dhillon H, Della-Fiorentina S, Richardson G, Trusket P, Goldstein D; on behalf of the AGITG. A pilot study of preoperative and postoperative chemotherapy in patients with operable gastric cancer: Australasian Gastrointestinal Trials Group Study 9601. <i>Australian and New Zealand Journal of Surgery</i> 2007; 77(4): 247–252.	AG9601
2007	109	GebSKI V, Burmeister B, Smithers MB, Foo K, Zalberg J, Simes J. Meta-analysis of the survival benefits from preoperative chemoradiation therapy and chemotherapy in oesophageal carcinoma. <i>Lancet Oncology</i> 2007; 8: 226–234.	IG9401
2007	110	Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. <i>New England Journal of Medicine</i> 2007; 357(20): 2040–2048.	CO.17
2007	111	Kopec JA, Yothers G, Ganz PA, Land SR, Cecchini RS, Wieand HS, Lembersky BC, Wolmark N. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06. <i>Journal of Clinical Oncology</i> 2007; 25(4): 424–430.	C-06
2007	112	Kuebler JP, Colangelo L, O'Connell MJ, Smith RE, Yothers G, Begovic M, Robinson B, Seay TE, Wolmark N. Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis. <i>Cancer</i> 2007; 110(9): 1945–1950.	C-07
2007	113	Kuebler JP, Wieand S, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. <i>Journal of Clinical Oncology</i> 2007; 25(16): 2198–2204.	C-07
2007	114	Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O'Connell MJ, Costantino JP, Wolmark N. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. <i>Journal of Clinical Oncology</i> 2007; 25(16): 2205–2211.	C-07
2007	115	Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptaszynski M, Parulekar W. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. <i>Journal of Clinical Oncology</i> 2007; 25(15): 1960–1966.	PA-13
2007	116	Verweij J, Casali PG, Kotasek D, LeCesne A, Reichard P, Judson IR, Issels R, Van Oosterom AT, Van Glabbeke M, Blay J-Y. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. <i>European Journal of Cancer</i> 2007; 43: 974–978.	EORTC 62005
2006	117	Cebon J, Hargreaves C, Stockler M, Nowak A, Dhillon H, Dickman B, GebSKI V; Australasian Gastro-Intestinal Trials Group (AGITG) AG0001H Investigators. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. <i>British Journal of Cancer</i> 2006; 95(7): 853–861.	AG0001H
2006	118	Cunningham D, Allum W, Stenning S, Thompson J, Van de Velde C, Nicolson M, Scarffe J, Lofts F, Falk S, Iveson T, Smith D, Langley R, Verma M, Weeden S, Chua Y, for the MAGIC trial participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. <i>New England Journal of Medicine</i> 2007; 355(1): 11-20.	MAGIC
2006	119	Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, Blay JY, Leyvraz S, Stul M, Casali PG, Zalberg J, Verweij J, Van Glabbeke M, Hagemeyer A, Judson I; On behalf of the EORTC Soft Tissue and Bone Sarcoma Group, The Italian Sarcoma Group and the Australasian Gastro-Intestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. <i>European Journal of Cancer</i> 2006; 42(8): 1093–103.	EORTC 62005
2006	120	Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral Uracil and Tegafur Plus Leucovorin Compared with Intravenous Fluorouracil and Leucovorin in Stage II and III Carcinoma of the Colon: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. <i>Journal of Clinical Oncology</i> 2006; 24(13): 2059-64.	C-06
2006	121	Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, Bertulli R, Colecchia M, Casali P, Pierotti M, Pilotti S. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. <i>Gastroenterology</i> 2004; 127(1): 294–299.	EORTC 62005
2006	122	Van Glabbeke M, Verweij J, Casali PG, Simes J, Cesne AL, Reichard P, Issels R, Judson IR, van Oosterom AT, Blay JY. Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC- IS G-AGITG). <i>European Journal of Cancer</i> 2006; 42(14): 2277–2285.	EORTC 62005
2005	123	Ackland SP, Jones M, Tu D, Simes J, Yuen J, Sargeant A-M, Dhillon H, Goldberg RM, Abdi E, Shepherd L, Moore MJ. A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer. <i>British Journal of Cancer</i> 2005; 93: 1235–1243.	AG9401

Year	No.	Manuscripts	Trial
2005	124	Burmeister BH, Smithers BM, GebSKI V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET, Denham JW, for the Trans-Tasman Radiation Oncology Group (TROG) and the Australasian Gastro-Intestinal Trials Group (AGITG) Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. <i>Lancet Oncology</i> 2005; 6(9): 659–668.	IG9401
2005	125	Goldstein D, Tan B, Rossleigh M, Haindl W, Walker B, Dixon J. Gastrointestinal stromal tumours: correlation of F-18-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response—an AGITG study. <i>Oncology</i> 2005; 69(4): 326-332.	EORTC 62005
2005	126	Van Glabbeke M, Verweij J, Casali P, Le Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom A, Goldstein D, Sciot R, Hogendoorn P, Brown M, Bertulli R, Judson I. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group– Australasian Gastro-Intestinal Trials Group Study. <i>Journal of Clinical Oncology</i> 2005; 23(24): 5795-5804.	EORTC 62005
2005	127	Zalcberg J, Verweij J, Casali P, Le Cesne A, Reichardt P, Blay J, Schlemmer M, Van Glabbeke M, Brown M, Judson I, EORTC Soft Tissue and Bone Sarcoma Group tISGAG-ITG. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. <i>European Journal of Cancer</i> 2005; 41(12): 1751-1757.	EORTC 62005
2004	128	Nowak A, Chow P, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. <i>European Journal of Cancer</i> 2004; 40(10): 1474-1484.	AG0001H
2004	129	Nowak A, Findlay M, Culjak G, Stockler M. Tamoxifen for hepatocellular carcinoma. <i>Cochrane Database of Systematic Reviews</i> 2004; (3): CD001024	AG0001H
2004	130	Verweij J, Casali P, Zalcberg J, Le Cesne A, Reichardt P, Blay J-Y, Issels R, van Oosterom A, Hogendoorn P, van Glabbeke M, Judson I, Bertulli R, Judson I, for the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group and the Australian Gastro- intestinal trials group: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. <i>Lancet</i> 2004; 364: 1127–1134.	EORTC 62005
2002	131	Kemeny M, Adak S, Gray B, Macdonald J, Smith T, Lipsitz S, Sigurdson E, O'Dwyer P, Benson Ar. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy—an intergroup study. <i>Journal of Clinical Oncology</i> 2002; 20(6): 1499–1505.	E9288
2001	132	Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, GebSKI V. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. <i>Annals of Oncology</i> 2001; 12(12): 1711- 1720.	AG9802
1996	133	Zalcberg J, Siderov J, Simes J. The role of 5-fluorouracil dose in the adjuvant therapy of colorectal cancer. <i>Annals of Oncology</i> 1996; 7(1): 42-46.	